Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : 2026 TeoTwawKi ... 2032 Darkest Interregnum -- Ignore unavailable to you. Want to Upgrade?

To: TobagoJack who wrote (211315)	2/14/2025 7:58:45 AM
From: Julius Wong	Read Replies (1) \| Respond to of 219584

Chinese biotech dominance in R&D is on the rise Jan. 18, 2025 3:56 PM ET By: Dulan Lokuwithana, SA News Editor Against a backdrop of rising U.S.-China geopolitical tensions, there are signs of growing dealmaking activity between Western pharmaceutical companies and Chinese biotechs, multiple research firms suggest. Large pharma companies have in-licensed nearly a third of their external molecules from Chinese biotechs in 2024, up from about 10%–12% in 2020–2022, Stifel said in a recent report highlighting China's recent dominance in biotech innovation. According to Evaluate Pharma, China's growing influence in pharmaceutical R&D is a key theme to watch in 2025. The pharma research group said that a Chinese company represents at least a fifth of R&D programs in the industry's total clinical pipeline. Merck's (NYSE: MRK) recent acquisition of rights to Chinese biotech LaNova Medicines' cancer candidate LM-299 in a deal worth up to $3.3B underscores Big Pharma's appetite for best-in- class assets from China. It was only a few months ago that ivonescimab, a PD-1/VEGF bispecific antibody similar to LM-299 developed by Summit Therapeutics ( SMMT) and its Chinese partner Akeso ( OTCPK:AKESF), outperformed MRK's blockbuster cancer drug Keytruda in a late-stage trial. According to Jefferies, U.S.-China pharma deals have also increased in size over the years, with an average out-licensing deal costing $389M in 2024 compared to $101M in 2021. Meanwhile, data from DealForma suggests that in the first 11 months of last year alone, major pharma companies have spent at least $3.15B in upfront cash and equity to license or acquire molecules originating from China. Obesity indicates a popular area of dealmaking for Big Pharma, as Eli Lilly ( LLY) and Novo Nordisk ( NVO) continue to operate a duopoly in that space. In 2023, AstraZeneca (NASDAQ: AZN) inked an exclusive license agreement with Shanghai-based Eccogene for an oral obesity candidate named ECC5004. Just last month, Merck (NYSE: MRK) followed up in-licensing a similar GLP-1-based weight loss therapy from Chinese biopharmaceutical company Hansoh Pharma ( OTCPK:HNSPF) in a deal worth up to $2B. In addition to Merck (NYSE: MRK) and Astra (NASDAQ: AZN), Roche ( OTCQX:RHHBY) ( OTCQX:RHHBF), Novartis ( NVS) ( OTCPK:NVSEF), AbbVie ( ABBV), and GSK ( GSK) were among other major drugmakers to boost their pipelines through licensing or buyout deals with Chinese companies last year. Noting that Chinese companies received $6B of upfront fees in licensing deals in 2024, prominent biotech investor Brad Loncar said that "Last year was just the start of that." “If some kind of protectionism is not put in place, it's going to have a big effect on the future smaller type of companies that exist in the U.S. and their chance of success," he added. Meanwhile, Stifel analysts were more optimistic. "The fact that the Chinese can develop biologics quickly and inexpensively is great news for patients and should motivate U.S. biotechs to do the same," they added.

To: TobagoJack who wrote (211315)	2/14/2025 12:23:34 PM
From: ggersh	Respond to of 219584

Bloomberg....... you just can't make Bloomberg shit up -vbg- Trump Gives Xi Chance to Court US Allies, Repair Global Image

To: TobagoJack who wrote (211315)	2/14/2025 12:28:58 PM
From: Box-By-The-Riviera™	1 Recommendation Recommended By ggersh Read Replies (2) \| Respond to of 219584

this is how jd vance sees the world through those tiny beady bug eyes. i can't even imagine what he sees while humping his sofa. but you'll love it, or you not love it. fire the messenger and i'll just put you on ignore. no worries. 'Threat I worry most is threat from within,' Vance criticises European leaders - summaryUS vice-president JD Vance has urged Europe to put forward a positive case for freedom and act against “the threat that I worry most, the threat from within” which he put as “the retreat of Europe from some of its most fundamental values” through restrictions on free speech, content moderation rules online, and political firewalls against radical parties. US vice-president JD Vance delivers his speech during the 61st Munich Security Conference in Munich. Photograph: Tobias Schwarz/AFP/Getty ImagesIn a wide-ranging and fiery speech peppered with European references, he accused European leaders of abandoning their roots as “defenders of democracy” during the cold war by what he believes is the process of shutting down dissenting voices ( 14:51). He said they were increasingly looking “like old entrenched interests hiding behind ugly Soviet era words like misinformation … who simply don’t like that idea that somebody with an alternative viewpoint might express a different opinion” ( 14:55). He criticised “cavalier” statements from European officials “sounding delighted” about the cancelled presidential elections in Romania or expansive content moderation powers or other free speech restrictions in the US, Germany and Sweden, saying there were “shocking to American ears” ( 14:46). He also criticised European leaders for “running in fear of your own voters,” including on migration, saying that risks destroying democracy from within by disenchanting the population from taking part in democratic processes ( 15:01). He dismissed any criticism of Elon Musk’s alleged interference in European elections, saying “if American democracy can survive 10 years of Greta Thunberg’s scolding, you guys can survive a few months of Elon Musk.” He called for an end of political “firewalls,” a pointed reference to the German arrangement keeping out the far-right parties such as the Alternative für Deutschland, just nine days before the federal election next Sunday ( 15:01). But notably, he doesn’t say much about Ukraine, other than a brief comment that the US administration “believes we can come to a reasonable settlement between Russia and Ukraine” ( 14:44).